Amneal Pharmaceuticals vs Jazz Pharmaceuticals
Jazz Pharmaceuticals reported revenue of $4.3 billion in fiscal 2025, 1.4 times Amneal Pharmaceuticals' $3.0 billion in fiscal 2025. Amneal Pharmaceuticals' revenue grew 8.1% in its latest year, and Jazz Pharmaceuticals' grew 4.9%. Amneal Pharmaceuticals had an operating margin of 13.1%, against -10.1% at Jazz Pharmaceuticals. Free cash flow was $270 million at Amneal Pharmaceuticals and $1.3 billion at Jazz Pharmaceuticals.
Side by side
| Amneal Pharmaceuticals | Jazz Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $3.0B | $4.3B |
| Revenue growth | 8.1% | 4.9% |
| Revenue growth a year, last 5 years | 8.7% | 12.5% |
| Gross margin | 36.9% | — |
| Operating margin | 13.1% | −10.1% |
| Net margin | 2.4% | −8.3% |
| Free cash flow | $270M | $1.3B |
| Free cash flow margin | 8.9% | 30.4% |
| Return on capital | 16.1% | −4.2% |
| Net debt to EBITDA | 3.8x | — |
| Dividends and buybacks | $0M | $125M |
| Change in diluted share count | 5.1% | −7.6% |
| Last close | $21.02 | $205.70 |
| P/E at the last close | 42.9× | 14.1× |
| Insider trades, last 12 months | sold $9.8 million | sold $68.0 million |
| Piotroski F-score | 7 of 9 | 4 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Amneal PharmaceuticalsJazz Pharmaceuticals
Operating margin
Percent of revenue
Amneal PharmaceuticalsJazz Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Amneal PharmaceuticalsJazz Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Amneal Pharmaceuticals and Jazz Pharmaceuticals pages.